N-hydroxy-N-[1-(6-phenylmethoxybenzo[b]fur-2-yl)ethyl] N'-methyl urea | 118564-85-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: N-hydroxy-N-[1-(6-phenylmethoxybenzo[b]fur-2-yl)ethyl] N'-methyl urea
• 英文别名: 1-Hydroxy-3-methyl-1-[1-(6-phenylmethoxy-1-benzofuran-2-yl)ethyl]urea
• CAS: 118564-85-5
• 化学式: C₁₉H₂₀N₂O₄
• 分子量: 340.379
• InChiKey: ZNOCFYCEOMJCSC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  74.9
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  异氰酸甲酯 、 4-苯甲氧基-2-羟基苯甲醛 生成 N-hydroxy-N-[1-(6-phenylmethoxybenzo[b]fur-2-yl)ethyl] N'-methyl urea
  参考文献：
  名称：

  Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting

  摘要：

  该公式化合物为：##STR1## 其中 R.sub.1 为(1) 氢，(2) C.sub.1 到 C.sub.4 烷基，(3) C.sub.2 到 C.sub.4 烯基，或(4) NR.sub.2 R.sub.3，其中 R.sub.2 和 R.sub.3 分别选自(1) 氢，(2) C.sub.1 到 C.sub.4 烷基和(3) 羟基，但 R.sub.2 和 R.sub.3 不能同时为羟基；其中 X 为氧、硫、SO.sub.2 或 NR.sub.4，其中 R.sub.4 为(1) 氢，(2) C.sub.1 到 C.sub.6 烷基，(3) C.sub.1 到 C.sub.6 烷酰，(4) 芳酰基，或(5) 烷基磺酰基；A 选自 C.sub.1 到 C.sub.6 烷基和 C.sub.2 到 C.sub.6 烯基；n 为1-5；Y 在每次出现时独立选择自(1) 氢，(2) 卤素，(3) 羟基，(4) 氰基，(5) 卤代烷基，(6) C.sub.1 到 C.sub.12 烷基，(7) C.sub.2 到 C.sub.12 烯基，(8) C.sub.1 到 C.sub.12 烷氧基，(9) C.sub.3 到 C.sub.8 环烷基，(10) C.sub.1 -C.sub.8 硫代烷基，(11) 芳基，(12) 芳氧基，(13) 芳酰基，(14) C.sub.1 到 C.sub.12 芳基烷基，(15) C.sub.2 到 C.sub.12 芳基烯基，(16) C.sub.1 到 C.sub.12 芳基氧基，(17) C.sub.1 到 C.sub.12 芳基硫代烷氧基，以及取代衍生物(18) 芳基，(19) 芳氧基，(20) 芳酰基，(21) C.sub.1 到 C.sub.12 芳基烷基，(22) C.sub.2 到 C.sub.12 芳基烯基，(23) C.sub.1 到 C.sub.12 芳基氧基，或(24) C.sub.1 到 C.sub.12 芳基硫代烷氧基，其中取代基选自卤素、硝基、氰基、C.sub.1 到 C.sub.12 烷基、烷氧基和卤代烷基；Z 为氧或硫；M 为氢、药用可接受阳离子、芳酰基或 C.sub.1 到 C.sub.12 烷酰，是 5-和/或 12-脂氧酶酶的有效抑制剂。还公开了抑制脂氧酶活性的化合物和抑制脂氧酶活性的方法。

  公开号：

  US04873259A1

文献信息

• Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a lipoxygenase inhibitor for treatment of asthma or chronic obstructive pulmonary disease
  申请人：Robinson B. Cynthia

  公开号：US20050090455A1

  公开（公告）日：2005-04-28

  A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a lipoxygenase inhibitor for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases.

  一种药物或兽药组合物，包括从去氢表雄酮和/或去氢表雄酮硫酸盐中选择的第一活性成分，以及包括一种脂氧合酶抑制剂的第二活性成分，用于治疗哮喘、慢性阻塞性肺病或其他呼吸系统疾病。该组合物以各种配方形式提供，并以套装形式提供。该专利的产品用于预防和治疗哮喘、慢性阻塞性肺病或其他呼吸系统疾病。
• Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds
  申请人：ABBOTT LABORATORIES

  公开号：EP0279263B1

  公开（公告）日：1993-08-04
• COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A LIPOXYGENASE INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
  申请人：Robinson Cynthia B.

  公开号：US20110209699A1

  公开（公告）日：2011-09-01

  A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a lipoxygenase inhibitor for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases.
• US4873259A
  申请人：——

  公开号：US4873259A

  公开（公告）日：1989-10-10
• Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting
  申请人：Abbott Laboratories

  公开号：US04873259A1

  公开（公告）日：1989-10-10

  Compounds of the formula: ##STR1## wherein R.sub.1 is (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl, (3) C.sub.2 to C.sub.4 alkenyl, or (4) NR.sub.2 R.sub.3, wherein R.sub.2 and R.sub.3 are independently selected from (1) hydrogen, (2) C.sub.1 to C.sub.4 alkyl and (3) hydroxyl, but R.sub.2 and R.sub.3 are not simultaneously hydroxyl; wherein X is oxygen, sulfur, SO.sub.2, or NR.sub.4, wherein R.sub.4 is (1) hydrogen, (2) C.sub.1 to C.sub.6 alkyl, (3) C.sub.1 to C.sub.6 alkoyl, (4) aroyl, or (5) alkylsulfonyl; A is selected from C.sub.1 to C.sub.6 alkylene and C.sub.2 to C.sub.6 alkenylene; n is 1-5; Y is selected independently at each occurrence from (1) hydrogen, (2) halogen, (3) hydroxy, (4) cyano, (5) halosubstituted alkyl, (6) C.sub.1 to C.sub.12 alkyl, (7) C.sub.2 to C.sub.12 alkenyl, (8) C.sub.1 to C.sub.12 alkoxy, (9) C.sub.3 to C.sub.8 cycloalkyl, (10) C.sub.1 -C.sub.8 thioalkyl, (11) aryl, (12) aryloxy, (13) aroyl, (14) C.sub.1 to C.sub.12 arylalkyl, (15) C.sub.2 to C.sub.12 arylalkenyl, (16) C.sub.1 to C.sub.12 arylalkoxy, (17) C.sub.1 to C.sub.12 arylthioalkoxy, and substituted derivatives of (18) aryl, (19) aryloxy, (20) aroyl, (21) C.sub.1 to C.sub.12 arylalkyl, (22) C.sub.2 to C.sub.12 arylalkenyl, (23) C.sub.1 to C.sub.12 arylalkoxy, or (24) C.sub.1 to C.sub.12 arylthioalkoxy, wherein substituents are selected from halo, nitro, cyano, C.sub.1 to C.sub.12 alkyl, alkoxy, and halosubstituted alkyl; Z is oxygen or sulfur; and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C.sub.1 to C.sub.12 alkoyl, are potent inhibitors of 5- and/or 12-lipoxygenase enzymes. Also disclosed are lipoxygenase inhibiting compositions and a method for inhibiting lipoxygenase activity.

  该公式化合物为：##STR1## 其中 R.sub.1 为(1) 氢，(2) C.sub.1 到 C.sub.4 烷基，(3) C.sub.2 到 C.sub.4 烯基，或(4) NR.sub.2 R.sub.3，其中 R.sub.2 和 R.sub.3 分别选自(1) 氢，(2) C.sub.1 到 C.sub.4 烷基和(3) 羟基，但 R.sub.2 和 R.sub.3 不能同时为羟基；其中 X 为氧、硫、SO.sub.2 或 NR.sub.4，其中 R.sub.4 为(1) 氢，(2) C.sub.1 到 C.sub.6 烷基，(3) C.sub.1 到 C.sub.6 烷酰，(4) 芳酰基，或(5) 烷基磺酰基；A 选自 C.sub.1 到 C.sub.6 烷基和 C.sub.2 到 C.sub.6 烯基；n 为1-5；Y 在每次出现时独立选择自(1) 氢，(2) 卤素，(3) 羟基，(4) 氰基，(5) 卤代烷基，(6) C.sub.1 到 C.sub.12 烷基，(7) C.sub.2 到 C.sub.12 烯基，(8) C.sub.1 到 C.sub.12 烷氧基，(9) C.sub.3 到 C.sub.8 环烷基，(10) C.sub.1 -C.sub.8 硫代烷基，(11) 芳基，(12) 芳氧基，(13) 芳酰基，(14) C.sub.1 到 C.sub.12 芳基烷基，(15) C.sub.2 到 C.sub.12 芳基烯基，(16) C.sub.1 到 C.sub.12 芳基氧基，(17) C.sub.1 到 C.sub.12 芳基硫代烷氧基，以及取代衍生物(18) 芳基，(19) 芳氧基，(20) 芳酰基，(21) C.sub.1 到 C.sub.12 芳基烷基，(22) C.sub.2 到 C.sub.12 芳基烯基，(23) C.sub.1 到 C.sub.12 芳基氧基，或(24) C.sub.1 到 C.sub.12 芳基硫代烷氧基，其中取代基选自卤素、硝基、氰基、C.sub.1 到 C.sub.12 烷基、烷氧基和卤代烷基；Z 为氧或硫；M 为氢、药用可接受阳离子、芳酰基或 C.sub.1 到 C.sub.12 烷酰，是 5-和/或 12-脂氧酶酶的有效抑制剂。还公开了抑制脂氧酶活性的化合物和抑制脂氧酶活性的方法。